Brief: Phio Pharmaceuticals Announces Positive DMC Recommendation
10/02/2023 13:03
Feb 10 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES POSITIVE DMC RECOMMENDATION
AND
CONTINUED ENROLLMENT OF ADVANCED MELANOMA STUDY WITHOUT
MODIFICATION
* PHIO PHARMACEUTICALS CORP - EXPECTS TO COMMENCE U.S. PHASE
1B
CLINICAL TRIAL EARLY IN H2 OF 2023
Source text for Eikon: ID:nPn5gHXGa
Further company coverage: PHIO.O
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing